American Chemical Society
Browse

Discovery of ANT3310, a Novel Broad-Spectrum Serine β‑Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii

Download (4 kB)
dataset
posted on 2020-12-11, 19:42 authored by David T. Davies, Simon Leiris, Magdalena Zalacain, Nicolas Sprynski, Jérôme Castandet, Justine Bousquet, Clarisse Lozano, Agustina Llanos, Laethitia Alibaud, Srinivas Vasa, Ramesh Pattipati, Ravindar Valige, Bhaskar Kummari, Srinivasu Pothukanuri, Cyntia De Piano, Ian Morrissey, Kirsty Holden, Peter Warn, Francesca Marcoccia, Manuela Benvenuti, Cecilia Pozzi, Giusy Tassone, Stefano Mangani, Jean-Denis Docquier, David Pallin, Richard Elliot, Marc Lemonnier, Martin Everett
The diazabicyclooctanes (DBOs) are a class of serine β-lactamase (SBL) inhibitors that use a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs. The first in-class drug, avibactam, as well as several other recently approved DBOs (e.g., relebactam) or those in clinical development (e.g., nacubactam and zidebactam) potentiate activity of β-lactam antibiotics, to various extents, against carbapenem-resistant Enterobacterales (CRE) carrying class A, C, and D SBLs; however, none of these are able to rescue the activity of β-lactam antibiotics against carbapenem-resistant Acinetobacter baumannii (CRAB), a WHO “critical priority pathogen” producing class D OXA-type SBLs. Herein, we describe the chemical optimization and resulting structure–activity relationship, leading to the discovery of a novel DBO, ANT3310, which uniquely has a fluorine atom replacing the carboxamide and stands apart from the current DBOs in restoring carbapenem activity against OXA-CRAB as well as SBL-carrying CRE pathogens.

History